Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus

Author： McLain L.   Durrani Z.   Wisniewski L.A.   Porta C.   Lomonossoff G.P.   Dimmock N.J.  

Publisher： Elsevier

ISSN： 0264-410X

Source： Vaccine, Vol.14, Iss.8, 1996-06, pp. : 799-810

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations. A comparison with other adjuvant systems

By Sjolander S.   Hansen J.-E.S.   Lovgren-Bengtsson K.   &   9kerblom L.   Morein B.  

Vaccine, Vol. 14, Iss. 4, 1996-03 ,pp. : 344-352

Elsevier

Access to resources Recommend Favorite

Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA

By Marinaro M.   Riccomi A.   Rappuoli R.   Pizza M.   Fiorelli V.   Tripiciano A.   Cafaro A.   Ensoli B.   De Magistris M.T.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3972-3981

Elsevier

Access to resources Recommend Favorite

Neutralizing antibodies against highly cytopathic Zairian human immunodeficiency type-1 virus (HIV-1) NDK are present in sera outside Africa

By Machado A.A.   Baknabua M.   Salaun D.   de Mareuil J.   Krciinak V.   MacGregor R.R.   Chermann J.-C.   Hirsch I.  

Vaccine, Vol. 13, Iss. 3, 1995-01 ,pp. : 321-325

Elsevier

Access to resources Recommend Favorite

Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine

By Cryz S.J.   Goldstein H.   Pettoello-Mantovani M.   Kim A.   Furer E.   Que J.U.   Hasler T.   Rubinstein A.  

Vaccine, Vol. 13, Iss. 1, 1995-01 ,pp. : 67-71

Elsevier

Access to resources Recommend Favorite

Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine

By Chujoh Y.   Matsuo K.   Yoshizaki H.   Nakasatomi T.   Someya K.   Okamoto Y.   Naganawa S.   Haga S.   Yoshikura H.   Yamazaki A.   Yamazaki S.   Honda M.  

Vaccine, Vol. 20, Iss. 5, 2001-12 ,pp. : 797-804

Elsevier

Access to resources Recommend Favorite